KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

GoodRx Holdings (GDRX) EBT (2019 - 2026)

GoodRx Holdings' EBT history spans 7 years, with the latest figure at $14.2 million for Q4 2025.

  • On a quarterly basis, EBT rose 24.4% to $14.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $56.5 million, a 79.71% increase, with the full-year FY2025 number at $56.5 million, up 79.71% from a year prior.
  • EBT hit $14.2 million in Q4 2025 for GoodRx Holdings, up from $6.1 million in the prior quarter.
  • Over the last five years, EBT for GDRX hit a ceiling of $19.6 million in Q2 2025 and a floor of -$46.6 million in Q3 2023.
  • Historically, EBT has averaged -$49100.0 across 5 years, with a median of $4.7 million in 2021.
  • Biggest five-year swings in EBT: tumbled 2154.52% in 2022 and later surged 5588.74% in 2025.
  • Tracing GDRX's EBT over 5 years: stood at $5.9 million in 2021, then tumbled by 180.83% to -$4.7 million in 2022, then plummeted by 419.18% to -$24.6 million in 2023, then surged by 146.31% to $11.4 million in 2024, then grew by 24.4% to $14.2 million in 2025.
  • Business Quant data shows EBT for GDRX at $14.2 million in Q4 2025, $6.1 million in Q3 2025, and $19.6 million in Q2 2025.